All Products
Men Care
Women Care
Sexual Wellness
Herbal & Homeopathy
Baby & Mom Care
Personal Care
Best Price *
TK
300.00
* Delivery will be done in Dhaka city only.
Alternative Product
More Information About - Linatab E - 10mg
Description
Generic Name
Empagliflozin + LinagliptinPrecaution
Not to be used in patients w/ type 1 diabetes. Immediately assess for ketoacidosis if symptoms eg, nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness occur. Discontinue treatment if ketoacidosis, necrotizing fasciitis of the perineum (Fournier's gangrene), pancreatitis, bullous pemphigoid is suspected or in clinical situations known to predispose to ketoacidosis (eg, prolonged fasting due to acute illness or surgery). Higher risk of ketoacidosis in patients on a very low carbohydrate diet, w/ an acute illness, pancreatic disorders suggesting insulin deficiency (eg, type 1 diabetes, history of pancreatitis or pancreatic surgery), insulin dose reduction (including insulin pump failure), alcohol abuse, severe dehydration & history of ketoacidosis. Evaluate for necrotizing fasciitis in patients who present w/ pain or tenderness, erythema, swelling in the genital or perineal area, fever, malaise. Combination w/ sulphonylurea or insulin. Patients for whom an empagliflozin-induced decrease in BP could pose a risk eg, patients w/ known CV disease, on antihypertensive therapy w/ history of hypotension or patients ?75 yr. Monitor carefully vol status (eg, physical exam, BP measurements, laboratory tests including haematocrit) & electrolytes in conditions that may lead to fluid loss (eg, GI illness). Complicated UTI including pyelonephritis & urosepsis. Cardiac failure (NYHA class I-IV). Positive test result for glucose in urine. Not to be used in patients w/ eGFR <60 mL/min/1.73 m2 or CrCl <60 mL/min. Assess renal function prior to treatment initiation & periodically during treatment; & prior to initiation of any concomitant medicines that may have negative impact on renal function. Avoid use during pregnancy. Discontinue breast feeding during treatment. Not recommended for use in childn <18 yr. Not recommended in elderly >85 yr.Indication
Type 2 Diabetes MellitusContra Indication
Severe renal impairment, end-stage renal disease, or dialysis Hypersensitivity to empagliflozin, linagliptin, or excipients (eg, anaphylaxis, angioedema, exfoliative skin conditions, urticaria, bronchial hyperreactivity)Dose
N/ASide Effect
>10% Urinary tract infection (11.4-12.5%) 1-10% Upper respiratory tract infection (7%) Nasopharyngitis (5.9-6.6%) Increased LDL-C (4.6-6.5%) Hypoglycemia (2.2-3.6%) Increased hematocrit (2.8%)Pregnancy Category
Name : Not Classified
Description
FDA has not yet classified the drug into a specified pregnancy category.Mode of Action
First combination approved by the FDA of a sodium glucose cotransporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor Empagliflozin: SGLT2 inhibitor; SGLT2 is expressed in the proximal renal tubules and is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen; SGLT2 inhibitors reduce glucose reabsorption and lower the renal threshold for glucose, thereby increasing urinary glucose excretion Linagliptin: DPP-4 inhibitor; increases and prolongs incretin hormone activity, which is inactivated by DPP-4 enzyme; incretins regulate glucose homeostasis by increasing insulin synthesis and release from pancreatic beta cells and reducing glucagon secretion from pancreatic alpha cellsInteraction
May increase risk of hypoglycemia w/ insulin & sulphonylureas. Interference w/ 1,5-anhydroglucitol (1,5-AG) assay. Empagliflozin: May add to the diuretic effect of thiazide & loop diuretics & may increase risk of dehydration & hypotension. Risk of decreased efficacy w/ UGT enzyme inducers. Linagliptin: Decreased exposure w/ rifampicin & reduced efficacy w/ strong P-gp or CYP450 isozyme CYP3A4 inducer.Pregnancy Category Note
Pregnancy Based on animal data showing adverse renal effects from empagliflozin, it is not recommended during the second and third trimesters of pregnancy There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy; an alternate diabetic therapy appropriate for pregnant women should be initiated Animal data In animal studies, empagliflozin, a component of the drug combination, resulted in adverse renal changes in rats when administered during a period of renal development corresponding to the late second and third trimesters of human pregnancy Doses approximately 13-times maximum clinical dose caused renal pelvic and tubule dilatations that were reversible No adverse developmental effects were observed when the combination of linagliptin and empagliflozin was administered to pregnant rats Lactation There is no information regarding presence in human milk, effects on breastfed infant, or effects on milk production; since potential for serious adverse reactions, including potential for empagliflozin to affect postnatal renal development, in a breastfed infant, advise patients that therapy is not recommended while breastfeeding; a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother should be initiatedAdult Dose
Type 2 Diabetes Mellitus Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when both empagliflozin and linagliptin are appropriate treatments. 10 mg/5 mg once daily in the morning. Dose may be increased to 25 mg/5 mg once daily if needed and tolerated. Hepatic impairment: No dose adjustment requiredChild Dose
N/ARenal Dose
Renal impairment eGFR >45 mL/min/1.73 m2: No dose adjustment required eGFR 30-45 mL/min/1.73 m2: Do not initiate drug eGFR < 30 mL/min/1.73 m2, end-stage renal disease (ESRD), or dialysis: Contraindicated Discontinued if eGFR is persistently drops to <45 mL/min/1.73 m2Administration
May be taken with or without foodDisclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.
Others Product
In Stock
Prescribed
In Stock
Prescribed
In Stock
Prescribed
In Stock
Prescribed
